Abulkhair, O. Et Al. 2012. Clinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study).. CANCER RESEARCH , vol.72 .

Abulkhair, O., Uslu, R., Sezgin, C., Bueyuekberber, S., Darwish, T., Isikdogan, A., ... Gumus, M.(2012). Clinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study).. CANCER RESEARCH , vol.72.

Abulkhair, O. Et Al. "Clinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study).," CANCER RESEARCH , vol.72, 2012

Abulkhair, O. Et Al. "Clinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study).." CANCER RESEARCH , vol.72, 2012

Abulkhair, O. Et Al. (2012) . "Clinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study).." CANCER RESEARCH , vol.72.

@article{article, author={O. Abulkhair Et Al. }, title={Clinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study).}, journal={CANCER RESEARCH}, year=2012}